Diasorin received US FDA clearance and a CLIA waiver for a multiplex group A streptococcus assay on its Liaison Nes point-of-care PCR instrument. The Liaison Nes Group A Strep test is designed to deliver results in about 15 minutes with less than one minute of hands-on time. Diasorin says the reagents can be stored at room temperature and that the compact, cloud-connected Nes platform supports real-time reporting in outpatient and decentralized settings. The group A strep test is the second cleared assay on the Nes platform, following a respiratory panel cleared in December for influenza A/B, RSV, and COVID-19. Angelo Rago, president of Diasorin’s Luminex subsidiary, tied the expansion to addressing high-impact infectious diseases. Diasorin also reiterated Nes revenue targets of more than $150 million in the US by 2030, previously outlined at an investor day. The clearance adds near-term breadth to the platform’s infectious disease menu, an area increasingly targeted by payers and clinicians seeking faster triage and stewardship.